Evidence map›Paper›PMID 33526007›Full record

ReviewBiological procedures online2021

Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review.

Jyoti Choudhary, Shrivardhan Dheeman, Vipin Sharma, Prashant Katiyar, Santosh Kumar Karn, Manoj Kumar Sarangi, Ankit Kumar Chauhan, Gaurav Verma, Nitin Baliyan

Open access · goldAbstract readReview
In one paragraph

Review in Biological procedures online, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond.European journal of drug metabolism and pharmacokinetics · 2023
    Review
  2. Dextran sulfate fromFrontiers in microbiology · 2023
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Nanotechnology and COVID-19:Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2022
    Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jyoti ChoudharyDepartment of Microbiology, Chinmaya Degree College (Hemwati Nandan Bahuguna Garhwal University, Srinagar, Garhwal, Uttarakhand), Haridwar, Uttarakhand, 249401, India.
Shrivardhan DheemanDepartment of Microbiology, School of Life Sciences, Sardar Bhagwan Singh University, Dehradun, Uttarakhand, 248161, India. svdheeman@gmail.com.
Vipin SharmaDepartment of Pharmaceuticals Sciences, Faculty of Ayurvedic and Medicinal Sciences, Gurukula Kangri Deemed to be University, Haridwar, Uttarakhand, 249404, India. vipin@gkv.ac.in.
Prashant KatiyarDepartment of Botany and Microbiology, Gurukula Kangri Deemed to be University, Haridwar, Uttarakhand, 249404, India.
Santosh Kumar KarnDeaprtment of Biotechnology and Biochemistry, School of Life Sciences, Sardar Bhagwan Singh University, Dehradun, Uttarakhand, 248161, India. santoshkarn@gmail.com.ORCID https://orcid.org/0000-0002-9803-4182
Manoj Kumar SarangiDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Dehradun, Uttarakhand, 248161, India.
Ankit Kumar ChauhanDepartment of Botany and Microbiology, Gurukula Kangri Deemed to be University, Haridwar, Uttarakhand, 249404, India.
Gaurav VermaDeaprtment of Microbiology, Shri Dev Suman Subharti Medical College, Ras Bihari Bose Subharti University, Dehradun, Uttarakhand, 248001, India.
Nitin BaliyanDepartment of Botany and Microbiology, Gurukula Kangri Deemed to be University, Haridwar, Uttarakhand, 249404, India.
Gurukul Kangri Vishwavidyalaya · INVeer Kunwar Singh University · INSubharti Medical College · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19, a pandemic of the 21st century caused by novel coronavirus SARS-CoV-2 was originated from China and shallowed world economy and human resource. The medical cures via herbal treatments, antiviral drugs, and vaccines still in progress, and studying rigorously. SARS-CoV-2 is more virulent than its ancestors due to evolution in the spike protein(s), mediates viral attachment to the host's membranes. The SARS-CoV-2 receptor-binding spike domain associates itself with human angiotensin-converting enzyme 2 (ACE-2) receptors. It causes respiratory ailments with irregularities in the hepatic, nervous, and gastrointestinal systems, as reported in humans suffering from COVID-19 and reviewed in the present article. There are several approaches, have been put forward by many countries under the world health organization (WHO) recommendations and some trial drugs were introduced for possible treatment of COVID-19, such as Lopinavir or Ritonavir, Arbidol, Chloroquine (CQ), Hydroxychloroquine (HCQ) and most important Remdesivir including other like Tocilizumab, Oritavancin, Chlorpromazine, Azithromycin, Baricitinib, etc. RT-PCR is the only and early detection test available besides the rapid test kit (serodiagnosis) used by a few countries due to unreasonable causes. Development of vaccine by several leader of pharmaceutical groups still under trial or waiting for approval for mass inoculation. Management strategies have been evolved by the recommendations of WHO, specifically important to control COVID-19 situations, in the pandemic era. This review will provide a comprehensive collection of studies to support future research and enhancement in our wisdom to combat COVID-19 pandemic and to serve humanity.

Indexed as

ACE-2 receptorCoronavirusCOVID-19Drug repurposing

Identifiers

PMID33526007
PMCPMC7849622
OpenAlexW3126772675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.